This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Roberto Spreafico, PhD
Senior Director, AI-Assisted Drug Discovery at Absci Corporation


Roberto Spreafico has 15 years of experience in computational immunology, including post-doctoral training at UCLA's Institute for Quantitative and Computational Biosciences. His publications have been cited over 5,000 times. He joined Absci in May 2021 to lead the AI-assisted antibody optimization program. Previously, he worked for several biotech and pharmaceutical companies, including Synthetic Genomics, Vir Biotechnology and GlaxoSmithKline. At Vir Biotechnology, he was computational lead for the development of Sotrovimab, a best-in-class COVID-19 mAb. Thanks to his broad expertise and training, he is particularly effective in bridging machine learning, experimental data generation and NGS/bioinformatics.

Agenda Sessions

  • In Silico Antibody Optimization Enabled by Quantitative Predictions of Affinity and Naturalness of Sequence Variants by Artificial Intelligence